<?xml version="1.0" encoding="UTF-8"?>
<p id="p0120">Azithromycin is a renowned antibacterial drug belongs to the class of macrolide antibiotics. It shows antibacterial activity by binding to bacterial 50s ribosomal subunit and represses the protein synthesis. It is commonly used in the treatment of pneumonia, sinusitis, lyme disease, skin infections and sexually transmitted diseases [
 <xref rid="bb0455" ref-type="bibr">91</xref>]. Apart from antibacterial activity, Azithromycin has antiviral activity observed in bronchial epithelial cells infected with rhinovirus, where it increased the production of interferon-stimulated genes [
 <xref rid="bb0460" ref-type="bibr">92</xref>]. Additionally, its antiviral activity was reported against Zika virus in human glial cells, where it prevented the virus induced alterations in fetal brain [
 <xref rid="bb0465" ref-type="bibr">93</xref>]. Also, the combination of hydroxychloroquine and azithromycin was found to be effective in SARS-CoV-2 associated pneumonia, where this combination significantly decreased the virus load and involved in the elimination of virus [
 <xref rid="bb0470" ref-type="bibr">94</xref>]. Energetics based modeling suggests that this drug combination might show the effect on SARS-CoV-2 spike-ACE2 complex. Recently Pfizer has reported the necessary data of azithromycin for SARS-CoV-2 clinical trials (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04321278" id="ir0250" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04321278</ext-link>) [
 <xref rid="bb0475" ref-type="bibr">95</xref>]. Another antibiotic and anti-tuberculosis drug Carrimycin being tested to treat the SARS-CoV-2 patients, currently, it is under clinical trials (
 <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT04286503" id="ir0255" xmlns:xlink="http://www.w3.org/1999/xlink">NCT04286503</ext-link>), however, its safety and efficacy need to be established in COVID-19 patients.
</p>
